Particle.news
AstraZeneca Investment Public Policy Drug Development Trade Relations Investigative Reporting Corporate Strategy Customs Tariffs Research and Development
The pharmaceutical giant posts 10% revenue growth, accelerates US manufacturing and R&D plans, and faces legal scrutiny in China over tax and data issues.
